Related Experiment Video

Updated: Nov 24, 2025

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

20.5K

Role of miRNAs in regulating responses to radiotherapy in human breast cancer

Zhi Xiong Chong1, Swee Keong Yeap2, Wan Yong Ho1

  • 1Faculty of Science and Engineering, University of Nottingham Malaysia, Selangor, Malaysia.

International Journal of Radiation Biology
|December 28, 2020
PubMed

Insights

MicroRNAs (miRNAs) are key regulators of breast cancer radiosensitivity and radioresistance. This review highlights 36 miRNAs involved in treatment response, offering insights for improving radiotherapy outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer is a leading global cancer in females.
  • Radiotherapy is a primary treatment, but radioresistance limits its efficacy.
  • MicroRNAs (miRNAs) are implicated as biomarkers and regulators in cancer.

Purpose of the Study:

  • To review the role of miRNAs in regulating breast cancer cell radiosensitivity and radioresistance.
  • To explore the cellular pathways associated with miRNA-mediated radio-responses.
  • To summarize current clinical research on miRNAs in breast cancer radiotherapy.

Main Methods:

  • Literature review of in vitro, in vivo, and clinical studies.
  • Identification and categorization of miRNAs involved in radio-responses.
  • Analysis of miRNA roles in radiosensitization and radioresistance.

Main Results:

  • Identified 36 miRNAs influencing radio-responses in breast cancer.
  • 22 miRNAs demonstrated radiosensitizing effects.
  • 12 miRNAs promoted radioresistance, and 2 had dual roles.

Conclusions:

  • MicroRNAs significantly modulate breast cancer response to radiotherapy.
  • Understanding these miRNA roles can inform strategies to overcome radioresistance.
  • Further clinical research is warranted to translate these findings into improved patient outcomes.
Keywords:
Breast cancermiRNAsradioresistanceradiosensitivityradiotherapy

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.8K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

621

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.4K